on April 18
th ,The Oceanpine Capital Investment Salon —— "
The Current Status and Development of the Pharmaceutical Industry" was successfully held in Beijing. The seminar invited the leaders of the State Food and Drug Administration, the founders and executives of the world's leading Chinese innovative drug company, and the founders and senior executives of leading investment institutions.
The main consensus of this seminar are:
1. The series of medical regulatory reforms that began in 2015 are very powerful, and their effects have initially appeared. We hope that the reforms will continue to be implemented to make China's medical industry stronger, so that people can use good medicines and afford medicines. Chinese pharmaceutical companies go global, and Chinese pharmaceutical companies have every opportunity to become world leaders.
2. It is necessary to seize the current good opportunity, regard the development of medicine, especially innovative medicines, as a national strategy, and provide support in terms of policies, funds, and personnel training.
3. In response to the problems encountered by the innovative drug industry at the clinical stage, such as the genetics office and clinical cooperation with tertiary hospitals, we hope that the country can issue policies to solve existing problems in a timely manner; address the problems faced by innovative drugs after they enter the market , Including the policies of the National Medical Insurance Bureau, industry supervision and other issues, I hope the country can pay attention to it, further encourage innovation, and support outstanding enterprises.
Source: Oceanpine Capital
